Cleo Diagnostics (ASX:COV) Revenue : A$ Mil (TTM As of Dec. 2023)

View and export this data going back to 2023. Start your Free Trial

What is Cleo Diagnostics Revenue?

Cleo Diagnostics's revenue for the six months ended in Dec. 2023 was A$0.00 Mil. Cleo Diagnostics does not have enough years/quarters to calculate its revenue for the trailing twelve months (TTM) ended in Dec. 2023. Cleo Diagnostics's Revenue per Share for the six months ended in Dec. 2023 was A$0.00. Cleo Diagnostics does not have enough years/quarters to calculate its Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate using Revenue per Share data.

Cleo Diagnostics Revenue Historical Data

The historical data trend for Cleo Diagnostics's Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cleo Diagnostics Revenue Chart

Cleo Diagnostics Annual Data

Trend

Jun23

Revenue

Cleo Diagnostics Semi-Annual Data
	Dec22	Jun23	Dec23
Revenue	-	-	-

Competitive Comparison of Cleo Diagnostics's Revenue

For the Medical Devices subindustry, Cleo Diagnostics's Revenue, along with its competitors' market caps and Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Cleo Diagnostics's Revenue Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Cleo Diagnostics's Revenue distribution charts can be found below:

* The bar in red indicates where Cleo Diagnostics's Revenue falls into.

Cleo Diagnostics Revenue Calculation

Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.

Cleo Diagnostics (ASX:COV) Revenue Explanation

In ranking the predictability, companies with more consistent revenue and earnings growth are ranked high with predictability.

Peter Lynch categorized companies according to their revenue growth:

Slow Grower: Inflation < 10-Year Revenue Growth Rate < 10%:
Stalwart: 10% < 10-Year Revenue Growth Rate < 20%:
Fast Grower: 10-Year Revenue Growth Rate > 20%:

His favorite companies are stalwart, those growing between 10-20% a year.

Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.

Be Aware

Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.

Cleo Diagnostics Revenue Related Terms

Thank you for viewing the detailed overview of Cleo Diagnostics's Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Cleo Diagnostics (ASX:COV) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Cleo Diagnostics Ltd (ASX:COV) » Definitions » Revenue

Comparable Companies

Traded in Other Exchanges

N/A

Address

480 Collins Street, Level 2, Melbourne, VIC, AUS, 3000

Website

https://www.cleodx.com

Cleo Diagnostics Ltd is focused on the development of non-invasive blood-based IVD tests to detect the presence, and recurrence, of ovarian cancer. The Company's first product to market is intended to be the Triage Test which has to date produced strong results to accurately differentiate patients with malignant ovarian cancer from those with benign gynaecological conditions. The Company aims to improve the diagnostic process and procedures for detecting ovarian cancer and, in this regard, improve quality-of-life outcomes for patients who have been diagnosed with ovarian cancer.

Cleo Diagnostics (ASX:COV) Headlines

No Headlines